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Abstract 
Cushing’s syndrome in western Sweden 
Degree project, Programme in Medicine 
Sofie Wengander 
Supervisor: Oskar Ragnarsson, MD, Associate professor 
2018, Department of Endocrinology, Sahlgrenska University Hospital, Gothenburg 
Introduction: Cushing’s syndrome (CS) is a rare endocrine syndrome caused by elevated 
cortisol levels. Endogenous CS is most often caused by adrenocorticotrophic hormone 
(ACTH) secreting pituitary tumours i.e. Cushing’s disease (CD), ACTH-secreting 
neuroendocrine tumours of other origin i.e. ectopic CS, cortisol producing adrenal adenomas, 
and in rarer cases adrenal carcinoma. Due to its rarity, epidemiological studies on CS are few. 
Objectives: The primary aim of this study was to analyze the incidence and prevalence of 
endogenous CS in western Sweden. Secondary aims were to validate the diagnostic codes 
used for CS and to evaluate the time span from debut of symptoms to remission. 
Methods: Medical records from patients diagnosed with CS in the West Götaland region 
2002-2017 were reviewed. In total, 234 patients had received a diagnostic code for CS. Of 
these, 80 patients had endogenous CS and were included in the study. 
Results: The incidence of endogenous CS was 3.1 per million per year, 1.5 for CD, 0.7 for 
benign adrenal CS, 0.1 for adrenal carcinoma, and 0.8 for ectopic CS.  
Validation of the diagnostic codes showed a sensitivity of 100% and a specificity of 70% for 
CD, and a sensitivity of 62% and a specificity of 93% for ectopic CS. Patients with adrenal 
CS were inconsistently coded with diagnostic codes of other specified CS and unspecified CS. 
For patients with CD, the time from debut of symptoms to remission was 30-46 months and 
 5 
24 months in patients with cortisol producing adrenal adenoma.  
Conclusions: 1) Benign adrenal CS and ectopic CS are more common than previously 
reported. 2) Specific diagnostic codes are needed for adrenal CS. 3) Patients with CS may 
have active disease for up to 4 years before adequate treatment has been provided.  
Key words: Cushing’s syndrome, incidence, prevalence, diagnostic codes, timeline 
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1. Introduction 
1.1 Cushing’s syndrome 
Cushing’s syndrome (CS) is a rare endocrine syndrome caused by prolonged exposure to 
elevated cortisol levels. Patients with CS often develop central obesity, hypertension, diabetes 
mellitus and osteoporosis. Depression and cognitive dysfunction are also frequently reported 
(1).  
In order to understand the clinical features and co-morbidities of CS, the pathophysiology of 
the syndrome needs to be explained. Synthetization and secretion of cortisol from the adrenal 
cortex is regulated through adrenocorticotropic hormone (ACTH) released from the anterior 
pituitary gland. Similarly, ACTH is regulated by corticotropin releasing hormone (CRH) from 
the hypothalamus. This neuroendocrine system acts through feedback mechanisms where 
high plasma cortisol concentrations reduces the secretion of ACTH from the pituitary gland 
(1).  
1.2 Aetiology 
Endogenous CS is either ACTH-dependent or ACTH-independent. The most common cause 
of ACTH-dependent CS is Cushing’s disease (CD), where elevated cortisol levels are most 
commonly caused by a benign ACTH-secreting pituitary adenoma, representing about 80% of 
all cases. ACTH-dependent CS can also originate from ACTH-secreting tumours such as 
small-cell lung carcinoma or other neuroendocrine tumours, collectively known as ectopic 
CS, accounting for about 20% of cases (2).  
ACTH-independent CS is caused by autonomous cortisol secretion, where benign cortisol 
producing adrenal adenomas represent about 60% of cases and cortisol producing adrenal 
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carcinomas 40%. Finally, rarer cases of ACTH-independent CS are macronodular hyperplasia 
and an inherited disease called primary pigmented adrenocortical disease (PPNAD) (2). 
A common cause of non-endogenous CS is iatrogenic CS due to long-term treatment with 
glucocorticoids. As a result of hypercortisolism, these patients present with similar clinical 
features as patients with endogenous CS. Furthermore, alcoholism, severe obesity and 
depression can induce supraphysiological cortisol production that mimics CS, a state named 
Pseudo CS (1).  
Adrenal adenomas incidentally discovered through imaging, so called incidentalomas, are 
found in 1-8% of the general population. In some of these cases, a mild hypersecretion of 
cortisol is present, a state named subclinical CS (1). Equally, pituitary incidentalomas are 
common with a rate of 10% among the normal population (2).  
	
Panel	1.	Aetiologies	of	Cushing’s	syndrome	(CS) 
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1.3 Diagnosis 
The diagnosis of CS is based on assessment of clinical features, biochemical testing and 
radiological imaging. Typical clinical features include rounded face, central obesity, purple 
striae, hypertension, glucose intolerance and psychiatric symptoms. The main biochemical 
analyses used to diagnose CS are urinary free cortisol, serum cortisol after dexamethasone 
suppression test and midnight serum or salivary cortisol (1). To determine the aetiology of 
CS, plasma ACTH-concentration is used to differentiate between ACTH-dependent and 
ACTH-independent CS. In patients with ACTH-dependent CS, MRI of the pituitary gland and 
sinus petrosus catheterization are usually used to differentiate between CD and ectopic CS 
while adrenal CT usually reveals cortisol producing adrenal adenoma in patients with ACTH-
independent CS (2).  
1.4 Treatments 
The primary treatment of CS is almost always tumor specific surgery. For CD, surgical 
removal of the pituitary tumor through transsphenoidal surgery (TSS) is the most common 
treatment and unilateral adrenalectomy for unilateral cortisol producing adrenal adenoma or 
carcinoma (1). Postoperatively, remission is confirmed by low serum cortisol concentrations 
(2).  
Medical therapies, usually with steroidogenesis inhibitors such as Ketoconazole and 
Metyrapone, are often used to lower cortisol levels prior to surgery. Pituitary radiotherapy is 
also a treatment option, mainly in patients who do not achieve remission after TSS (2). After 
TSS and especially radiotherapy, the patient has a risk of developing hypopituitarism (growth 
hormone deficiency, hypogonadism and hypothyroidism). In patients who do not achieve 
remission after treatment with surgery or radiation, bilateral adrenalectomy is the treatment of 
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choice. Surgical removal of both adrenal glands is always curative for ACTH-dependent CS, 
but results in life-long glucocorticoid and mineralocorticoid deficiency (1). After bilateral 
adrenalectomy in patients with CD, a concern is that the remaining pituitary tumor continues 
to grow and secrete large amounts of ACTH that results in hyperpigmentation, a state called 
Nelson’s syndrome (2). 
1.5 Morbidity and mortality 
Initially described by Harvey Cushing, CS is associated with increased morbidity and 
mortality (3). Today, patients with incompletely treated CS sill have up to five-hold increased 
mortality rate compared to the general population (4). However, mortality in patients in long-
term remission is still debated. In a study including patients with CS of all aetiologies, 
mortality was reported to be similar as compared to the general population (5). In another 
study on CD, mortality was significantly increased (6). This difference is probably explained 
by the heterogeneity of the patients, duration of hypercortisolism, treatment methods and 
definition of remission.  
Despite clinical and biochemical long-term remission, co-morbidities remain high in patients 
with CS. Patients with CD in long-term remission maintain a high cardiovascular risk (7) and 
similarly, patients with CD or adrenal CS have an increased risk of myocardial infarction, 
stroke and venous thromboembolism (8). Duration of hypercortisolism before CS diagnosis 
may predict increased mortality (9), emphasizing the importance of early recognition and 
treatment to reduce symptoms, co-morbidities and mortality. 
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1.6 Epidemiology 
Due to its rarity, and heterogeneity, studies on CS are few. In particular epidemiological 
studies on the incidence and prevalence of CS. A Danish study from 2001 reported an 
incidence of 1.2 to 1.7 per million per year for CD, 0.6 per million per year for cortisol 
producing adrenal adenoma and 0.2 per million per year for adrenal carcinoma (4). A study 
from New Zeeland, published in 2011, estimated the prevalence of CS to be 79 cases per 
million and the incidence to be 1.8 per million per year, excluding adrenal carcinoma and 
malignant ectopic CS (10). In 2014, a study from the US estimated the total incidence of CS 
to be 49 cases per million per year and for only CD, nearly 8 cases per million per year (11), a 
considerably higher incidence rate than previously reported. These findings suggest that data 
on incidence and prevalence of endogenous CS needs further evaluation.  
The primary aim of this study was to analyze the incidence and prevalence of endogenous CS 
in western Sweden from 2002 to 2017. Secondary aims were to validate the diagnostic codes 
used for CS and to evaluate the time span from debut of symptoms to recognition, diagnosis, 
treatment and remission for patients with CS. 
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2. Specific scientific questions 
• What is the incidence and prevalence of endogenous CS in West Götaland Region 
during the period 2002-2017? 
• How many patients registered with diagnostic ICD-10 codes used for CS actually have 
the syndrome? 
• What is the time span from debut of symptoms through recognition, diagnosis, and 
treatment, to remission in patients with endogenous CS? 
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3. Methods 
3.1 Study design and description of the area of coverage 
This was a retrospective chart review of all patients diagnosed with CS in the West Götaland 
Region, Sweden during the period from 2002 to 2017. At the end of the study (December 31, 
2017), the West Götaland Region had a population of 1 690 782 (National database of 
statistics, Sweden, SCB). 
There are seven hospitals in the West Götaland Region; the Sahlgrenska University Hospital 
in Göteborg, with departments of endocrinology, endocrine surgery and neurosurgery, and six 
local hospitals with endocrine departments. All patients with suspected CS in West Götaland 
Region are referred to the Sahlgrenska University Hospital for evaluation and treatment.  
 
3.2 Identification of patients 
All hospital visits in Sweden are coded in a diagnosis-related group (DRG) registry.  
To identify patients with CS, a search in the DRG-registry at the Sahlgrenska University 
Hospital was performed for the following ICD-10 codes: Pituitary-dependent CS (E24.0), 
Nelson’s syndrome (E24.1), Iatrogenic CS (E24.2), Ectopic ACTH-syndrome (E24.3), 
Alcohol-induced CS (E24.4), Other specified CS (E24.8) and Unspecified CS (E24.9).  
Patients excluded from the analysis were; a) patients with endogenous CS not living in the 
West Götaland Region at the time of diagnosis, i.e. patients from other countries or other 
regions in Sweden, b) patients who, after review of clinical, biochemical and imaging data, 
did not have the diagnosis of endogenous CS confirmed, including patients with iatrogenic CS 
and pseudo CS, and c) patients who had received CS diagnosis in the West Götaland Region 
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before 2002. The last group was however included in the calculation of prevalence rates. 
 
3.3 Collection and validation of data 
Medical records for identified patients at all hospitals in the West Götaland Region (including 
the hospitals in Göteborg, Borås, Trollhättan, Skövde, Uddevalla, Alingsås and Lidköping), 
available through the electronic journal database at the Sahlgrenska University Hospital, were 
reviewed.  
A Microsoft Excel file, including pre-defined variables, was created to collect patient data in a 
structured manner. In patients where exact dates of biochemical testing, diagnosis, treatments, 
visits and other variables were missing, the dates were roughly estimated to month and year. 
For some variables, data were unknown or missing. For these variables, calculations were based 
on the available data.  
3.3.1 Validation of the CS diagnosis 
Clinical features, biochemical data, imaging and histopathological diagnosis of all patients 
diagnosed with CS in the West Götaland Region from 2002 to 2017 were evaluated by the 
authors through chart review to validate the diagnosis of CS. 
Biochemical data from patients with ACTH-independent CS (together with imaging results) 
were usually sufficient to confirm aetiology. However, in patients with ACTH-dependent CS, 
biochemical testing (and imaging) were rarely conclusive for a specific aetiology, i.e. ACTH-
secreting pituitary adenoma or ectopic CS. In most cases, sinus petrosus catheterization together 
with histopathological examination, were the cardinal methods to determine aetiology. Patients 
with adrenal incidentalomas and pathological dexamethasone suppression test, without typical 
clinical features of hypercortisolism, were classified as subclinical CS. 
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Sensitivity and specificity of the diagnostic codes for CD (E24.0), Iatrogenic CS (E24.2) and 
Ectopic CS (E24.3) were calculated, based on how many patients with endogenous CS who had 
received an adequate code and how many patients without endogenous CS had received an 
inappropriate diagnostic code. 
3.3.2 Referral and first visit 
The first visit at the referring doctor who suspected CS was reviewed, as well as the first visit 
at the Sahlgrenska University Hospital, usually the first visit at the department of 
endocrinology. 
3.3.3 Duration of symptoms and clinical features 
Duration of symptoms (months) was estimated through chart review. This estimation was most 
often based on the patients’ own description of debut of characteristic symptoms of CS such as 
weight gain and fatigue. Presence of and/or treatment for hypertension and diabetes at the time 
of CS diagnosis were also recorded.  
3.3.4 Biochemical testing 
Results from the following biochemical tests were recorded; a) 1-3 measurements of 24-hr 
urinary free cortisol (UFC), b) serum cortisol after low-dose (1 mg) overnight dexamethasone, 
c) serum cortisol after 48-hr (0.5 mg x 4 for 48 hrs) dexamethasone suppression, d) morning (8 
AM) plasma ACTH-concentrations and e) midnight serum cortisol. The upper limit of the 
normal (ULN) for UFC was also noted, since assays, and thereby normal reference ranges, were 
different between hospitals and/or changed during the study period. 
In some patients, all of the above mentioned biochemical tests were performed, but in many 
cases, not all tests were required for diagnosis. For example, in patients with a typical clinical 
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picture and very high UFC, a dexamethasone suppression test did not add any further 
information to the diagnostic process.  
3.3.5 Imaging 
In patients with ACTH-dependent CS, results of conventional pituitary MRI, dynamic pituitary 
MRI, CT abdomen and CT thorax were collected. In patients with ACTH-independent CS, 
results of CT adrenal were recorded. 
3.3.6 Invasive testing 
Among most patients with ACTH-dependent CS, the aetiology could not be fully confirmed 
until sinus petrosus catheterization had been performed, indicating localization of the tumor. 
Adrenal vein catheterization was performed in rare cases of CS with bilateral adrenal lesions 
on CT, where cortisol and aldosterone concentrations were used to determine lateralization. 
 
Panel	2. The	diagnostic	process	of	Cushing’s	syndrome	(CS) 
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3.3.7 Aetiology 
The diagnostic process of CS is known to be complex and includes evaluation of clinical 
features, biochemical tests, invasive tests and imaging as explained above. In this study, 
diagnosis and aetiology was usually determined by an endocrinologist in accordance to 
recommended diagnostic criteria at the time of diagnosis (12).  
The aetiology of CS in the patients of the current study were confirmed by authors through 
chart review. Benign ACTH-secreting pituitary adenomas and aggressive ACTH-secreting 
pituitary adenomas or carcinomas were classified as CD. ACTH-secreting tumors originating 
from outside of the pituitary region were classified as ectopic CS. Benign cortisol producing 
adrenal adenoma, PPNAD and macronodular hyperplasia were classified as benign adrenal CS 
and malignant cortisol producing adrenal tumors as adrenal carcinoma. 
3.3.8 Treatments 
All treatments that the patients had received were recorded as well as curative treatment. 
Curative treatment was defined as TSS or unilateral adrenalectomy with low cortisol levels 
postoperatively, or bilateral adrenalectomy. Pituitary radiotherapy was considered curative 
when the patients subsequently developed normocortisolemia or adrenal insufficiency.  
3.3.9 Remission and recurrence 
Remission status post operatively was determined through chart review and based on one or 
more of the following criteria; 1) Low cortisol level after TSS or unilateral adrenalectomy 2) 
Resolution of clinical symptoms and features after treatment 3) Normalization of UFC 4) 
Normalization of cortisol 24-hr variation 5) Adequate suppression of cortisol after 
dexamethasone suppression test 6) Adrenal insufficiency and/or glucocorticoid dependency 7) 
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Bilateral adrenalectomy. Remission status at the last clinical visit was categorized in a similar 
manner. 
Date of remission was set to the date of the curative treatment when the patient achieved 
remission, for example when a patient had low cortisol levels after the first TSS.  Recurrence 
of CS was defined as clinical and biochemical signs of CS in patients after previously been 
considered in remission.  
3.3.10 Histopathology 
Histopathological reports from the tumor tissue that was removed during surgery were 
reviewed. In patients with CD, the immunohistological findings were reviewed as well. 
3.3.11 Death 
Date to death was recorded and available in all patients who had died.  
 
3.4 Statistics 
3.4.1 Incidence and prevalence 
The incidence rates of endogenous CS in West Götaland Region were calculated by dividing 
the total number of patients diagnosed with CS between 2002 and 2017 with the mean 
population rate of West Götaland region from 2002 through 2017 multiplied by 16 (the 
number of years included in the study). According to the national database of statistics in 
Sweden (SCB) the population of West Götaland Region was 1 500 857 at December 31, 2001 
and 1 690 782 at December 31, 2017. Calculations on incidence were performed separately 
for CD, benign adrenal CS (including cortisol producing adrenal adenoma, macronodular 
hyperplasia and PPNAD), cortisol producing adrenal carcinoma and ectopic CS. 
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Prevalence was estimated by dividing the number of patients diagnosed with CS between 
2002 and 2017, as well patients diagnosed with CS before 2002, who were alive at the end of 
the study, with the population rate of West Götaland region at December 31, 2017. Prevalence 
rates were calculated separately for CD, benign adrenal CS, adrenal carcinoma and ectopic 
CS. 
3.4.2 Timeline 
To evaluate the time span from debut of symptoms to recognition, diagnosis, treatment and 
remission, a timeline was created to visualize the time from debut of symptoms to remission 
for patients with endogenous CS. Calculations were made separately for CD, benign adrenal 
CS, adrenal carcinoma and ectopic CS.  
Time-differences between dates for the following variables were calculated: the first visit at 
referral doctor to diagnosis CS, diagnosis CS to the first attempted curative treatment, and the 
first attempted curative treatment to remission.  
3.4.3 Statistical methods 
Descriptive data are presented as mean ± SD or median (range; interquartile range). For 
comparison between two groups, unpaired T-test was used for normally distributed data and 
Mann-Whitney U-test for non-normally distributed data. For proportions, Pearson Chi-square 
or Fishers exact test were used. A P-value <0.05 was considered statistically significant. 
Statistical analyses were performed using SPSS version 25.  
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4. Ethics 
The ethical committee of the University of Gothenburg, Göteborg, Sweden approved the 
study. The study was conducted according to the Declaration of Helsinki.  
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5. Results 
5.1 Validation of the CS diagnosis 
By a search for the diagnostic codes of CS in the DRG-registry, registered between 2002 and 
2017 in the West Götaland Region, 234 patients were identified (Figure 1).  
 
Figure	1. Identified	patients	who	had	received	a	diagnostic	code	for	Cushing’s	syndrome	(CS)	
 
In total, 38 patients (26 women and 12 men) had ACTH-secreting pituitary adenoma and one 
female patient had an aggressive ACTH-secreting pituitary tumour. Thus, 39 patients were 
diagnosed with CD. The aetiology was confirmed through histopathological diagnosis in 30 
(77%) of the patients with ACTH-secreting pituitary adenoma and in the patient with 
aggressive ACTH-secreting pituitary tumour. In four patients with CD the histopathological 
examination showed normal pituitary tissue (three of these patients were in remission 
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postoperatively and one patient was not in remission) and in five patients, histopathological 
data was missing.  
Sinus petrosus catheterization was conducted in 37 patients and confirmed CD in 31 patients 
and ectopic CS in six patients. Six patients with CD who were not investigated with sinus 
petrosus catheterization had a pituitary macroadenoma (>8mm) and data were missing for two 
patients. Thus, in 36 of 39 patients with CD (92%), the diagnosis was confirmed with 
histopathological examination and/or sinus petrosus catheterization. 
All 39 patients with CD had received the diagnostic code for pituitary-dependent CS, E24.0 
(Figure 2). Seventeen patients who had received E24.0 did not have CD. Thus, the sensitivity 
and specificity of the diagnostic code were 100% and 70%, respectively. 
Twenty-one patients were diagnosed with ectopic CS (13 women and 8 men).  In nine 
patients, the primary tumour was localized in the lungs. Four patients had histologically 
confirmed small cell lung carcinoma with metastases. Four had had received the diagnosis 
lung cancer (of which three also had liver metastases) based on imaging, three of these 
without histopathological diagnosis and one with histologically confirmed brain metastases 
from neuroendocrine carcinoma. One patient had a histologically confirmed ACTH-positive 
neuroendocrine lung tumour. In four patients with ectopic CS, the primary tumour was 
localized in the pancreas of which all had histologically confirmed pancreatic neuroendocrine 
cancer with liver metastases. One patient had a histologically confirmed thymus carcinoid 
with skeletal metastases, one patient had a histologically confirmed small intestine carcinoid 
with multiple metastases and in one patient with spread metastases, the primary tumour was 
assumed to be prostate cancer. In five patients, the localization of the ACTH-secreting tumour 
was unknown despite biochemical, imaging and histopathological examination (occult ectopic 
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CS). Two of these five patients had metastatic disease proven through imaging and three had 
performed sinus petrosus catheterization that confirmed the diagnosis. 
Thirteen (62%) of the patients with ectopic CS received the correct diagnostic code E24.3 for 
ectopic CS, two patients received E24.0 (Pituitary-dependent CS), three patients E24.8 (Other 
specified CS) and three patients E24.9 (Unspecified CS). One patient who had received E24.3 
did not have ectopic CS. Thus, the sensitivity and specificity of the diagnostic code were 62% 
and 93%, respectively. 
Of 17 patients with benign adrenal CS, 14 had a unilateral cortisol producing adrenal 
adenoma (13 women and one man), histologically confirmed in 13 patients (missing for one 
patient). In one patient with bilateral adrenal lesions on CT, unilateral cortisol producing 
adrenal adenoma was confirmed through adrenal vein catheterization. Two female patients 
had histologically confirmed PPNAD and one male patient had histologically confirmed 
macronodular hyperplasia. Bilateral cortisol production in the patients with PPNAD and 
macronodular hyperplasia were confirmed by adrenal vein catheterization. Thus, in 16 of 17 
patients with benign adrenal CS (94%), the diagnosis was confirmed through 
histopathological examination and/or adrenal vein catheterization. 
The diagnostic codes used for the patients with benign adrenal adenoma were E24.8 (Other 
specified CS, N=7) and E24.9 (Unspecified CS, N=7). One of the patients with PPNAD 
received the diagnostic code E24.8 (Other specified CS) and the other received E24.9 
(Unspecified CS). The patient with macronodular hyperplasia received E24.9 (Unspecified 
CS).  
Three patients had histologically confirmed adrenocortical cancer with metastases. The 
diagnostic codes used were E24.8 (Other specified CS, N=1) and E24.9 (Unspecified CS, 
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N=1). The third patient, known by the authors, had not received a diagnostic code for CS. All 
three patients with cortisol producing adrenal carcinoma received the diagnostic code for 
adrenocortical cancer, C74.0.  
	
 
Figure	2. Validation	of	the	diagnostic	codes	for	Cushing’s	syndrome	(CS) 
 
Twenty-four patients had iatrogenic CS due to long-term treatment with glucocorticoids. 
Underlying diseases of these patients were brain tumors, rheumatoid arthritis, inflammatory 
bowel disease, asthma and other conditions treated with glucocorticoids. Nineteen of the 
patients with iatrogenic CS received the adequate diagnostic code of E24.2, two received 
E24.8 (Other specified CS), one E24.0 (Pituitary-dependent CS) and two E24.9 (Unspecified 
CS). One patient who had received E24.2 did not have iatrogenic CS. Thus, the sensitivity 
and specificity of the diagnostic code were 79% and 95%, respectively. 
Twenty-one patients had adrenal incidentalomas with subclinical CS, of which eight 
underwent unilateral adrenalectomy and five received medical therapy. The diagnostic codes 
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used for patients with subclinical CS were E24.8 (Other specified CS, N=8) and E24.9 
(Unspecified CS, N=13) 
Ten patients were initially suspected to have CS. In five, CS was ruled out after clinical and 
biochemical evaluation, three had pseudo CS; one due to high alcohol intake, one from 
depression and one from eating disorder. Furthermore, two patients had a suspected CS but 
refused evaluation and one patient with suspected CS was never evaluated for an unknown 
reason. Finally, eight patients had other endocrine diagnoses and seven had non-endocrine 
diagnoses (Figure 3).  
 
Figure	3. Identified	patients	who	did	not	have	Cushing’s	syndrome	(CS) 
 
Of the 234 identified patients who had received a diagnostic code for CS, 17 patients with 
endogenous CS were excluded for not living in the West Götaland region and charts for two 
patients were missing. Additionally, 54 patients had received a diagnosis for endogenous CS 
before 2002 (Figure 1). 
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5.2 Demographics 
After review of clinical, biochemical, imaging and histopathological data, 80 patients (56 
women and 24 men) fulfilled the inclusion criteria. In total, 60 patients had ACTH-dependent 
CS; 39 patients had CD (38 patients had a benign pituitary adenoma and one patient an 
aggressive ACTH-secreting pituitary tumor) and 21 patients had ectopic CS. 
Twenty patients had ACTH-independent CS; 14 patients had cortisol producing adrenal 
adenoma, two patients had PPNAD, one had macronodular hyperplasia and three had cortisol 
producing adrenal carcinoma. Patient demographics and causes of endogenous CS are shown 
in Table 1.  
Table	1.	Patient	demographics	and	aetiology	of	endogenous	Cushing’s	syndrome	(CS)	
	
 
Data	are	presented	as	mean	(SD)	and	N	(%).	
*Ages	of	patients. 
 
The mean age at diagnosis for endogenous CS was 50 years (SD 18), 47 years for women (SD 
18) and 57 years for men (SD 16). For CD, mean age at diagnosis was 48 years (SD 17), for 
benign adrenal CS 44 years (SD 16) and for ectopic CS 59 years (SD 18). Patients with 
ectopic CS were significantly older at diagnosis compared to patients with CD (P=0.028) and 
patients with benign adrenal CS (P=0.014). The three patients with cortisol producing adrenal 
carcinoma were 29, 43 and 52 years old at diagnosis. Age distribution for all patients with 
endogenous CS are shown in Figure 4.  
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Of all patients with endogenous CS, 56 (70%) were women. For CD, 27 (69%) patients were 
women, for benign adrenal CS 15 (88%) and for ectopic CS 13 (62%). Among the three 
patients with adrenal carcinoma, one was a woman (33%). Of the 80 patients with 
endogenous CS, 59 (74%) had hypertension at diagnosis CS and 26 (33%) had diabetes 
mellitus at diagnosis (Table 1). 
 
5.3 Incidence and prevalence 
The total incidence of endogenous CS in the West Götaland region between 2002 to 2017 was 
3.1 per million per year. The number of new cases with endogenous CS varied over the years, 
the lowest rates were in 2003 when only one patient was diagnosed with benign adrenal CS 
compared to 2013 when 11 new cases of endogenous CS were reported (Figure 5).  
	
 
Figure	4. 	Age	distribution	for	patients	with	endogenous	Cushing’s	syndrome	(CS) 
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Figure	5. Annual	incidence	of	endogenous	Cushing’s	syndrome	(CS)	in	the	West	Götaland	Region	2002-2017 
 
At the end of the study, five of 54 patients who were diagnosed with endogenous CS before 
2002 were not living in the West Götaland region and ten had died. Of the 80 patients 
diagnosed with CS between 2002-2017, four patients were not living in the West Götaland 
region and 22 patients had died at the end of the study (18 patients with ectopic CS, 2 patients 
with adrenal carcinoma and 2 patients with CD). In total, 93 patients were included in the 
prevalence calculations, 54 patients diagnosed between 2002 and 2017 and 39 diagnosed 
before 2002 (24 patients with CD and 15 with benign adrenal CS). Thus, the prevalence of 
endogenous CS in the West Götaland region at the end of the study was 57 per million.  
Incidence rate for CD during the study period was 1.5 per million per year and the total 
prevalence was 36 per million. For benign adrenal CS (including cortisol producing adrenal 
adenoma, PPNAD and macronodular hyperplasia) the incidence was 0.7 per million per year 
and the prevalence was 19 per million. For cortisol producing adrenal carcinoma, the 
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incidence was 0.1 per million per year and the prevalence was 0.6 per million. The incidence 
rate for ectopic CS was 0.8 per million per year and the prevalence was 1.8 per million (Table 
2). 
Table	2.	Incidence	and	prevalence	of	endogenous	Cushing’s	syndrome	(CS)	in	the	West	Götaland	region	
 
 
5.4 Timeline 
A timeline was created to visualize the time span for the patients from debut of symptoms 
through first visit at the referral doctor, diagnosis, first treatment and curative treatment, to 
remission. For one patient with CD, dates for the first visit at referral doctor and diagnosis 
were missing and the patient was excluded from the calculations. Data from the timeline 
analysis is shown in Table 3. 
Table	3.	Timeline	data	for	patients	with	endogenous	Cushing’s	syndrome	(CS)	
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Data	are	median	(range)	and	interquartile	[range]	
*	Analysis	is	performed	on	patients	with	CD	and	benign	adrenal	CS,	women	(N=41)	and	men	(N=14) 
P0:	Mann-Whitney	U-test,	women	compared	to	men 
P1:	Mann-Whitney	U-test,	CD	compared	to	ectopic	CS 
P2:	Mann-Whitney	U-test,	benign	adrenal	CS	compared	to	ectopic	CS 
P3:	Mann-Whitney	U-test,	CD	compared	to	benign	adrenal	CS	
 
5.4.1 Duration of symptoms 
The duration of symptoms prior to diagnosis was 12 months (range 0-120, interquartile range 
2-30) for all endogenous CS. For CD, the duration of symptoms was 24 months (range 0-120, 
interquartile range 12-48), for benign adrenal CS 18 months (range 0-108, interquartile range 
7-30) and for ectopic CS one month (range 0-30, interquartile range 0-5). The three patients 
with cortisol producing adrenal carcinoma had duration of symptoms of 0, 5 and 7 months. 
The duration of symptoms in patients with CD and benign adrenal CS was significantly 
longer compared to patients with ectopic CS (P<0.001). No significant difference in duration 
of symptoms was found between CD and benign adrenal CS (P=0.251). 
In patients with CD or benign adrenal CS, the duration of symptoms were 24 months for 
women (range 0-120, interquartile range 12-36) and 21 months for men (range 0-60, 
interquartile range 6-48). There was no significant difference between women and men 
(P=0.509). 
5.4.2 Time from first visit at referral doctor to diagnosis CS 
The diagnosis CS was already established in 16 patients with endogenous CS at some of the 
six local hospitals in West Götaland region when admitted to the department of endocrinology 
at the Sahlgrenska University Hospital. 
The time from first visit at referral doctor to confirmed diagnosis of CS for all endogenous CS 
was 56 days (range 0-708, interquartile range 15-112). For CD, 69 days (range 0-708, 
interquartile range 29-120), benign adrenal CS, 100 days (range 7-613, interquartile range 65-
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190), and ectopic CS 14 days (range 0-374, interquartile range 6-47). The time from first visit 
to diagnosis CS in the patients with adrenal carcinoma was 0, 7 and 47 days. The time from 
first visit to diagnosis of CD and benign adrenal CS was significantly longer compared to 
diagnosis of ectopic CS (P=0.003 and P<0.001, respectively). There was no significant 
difference between CD and benign adrenal CS (P=0.092).  
In patients with CD or benign adrenal CS, the time to diagnosis were 76 days for women 
(range 0-708, interquartile range 34-166) and 59 days for men (range 3-613, interquartile 
range 23-166; P=0.324). 
5.4.3 Time from diagnosis CS to first treatment  
First treatment was defined as the first attempted curative treatment, for example TSS or 
unilateral adrenalectomy. Medical therapy was given preoperatively in 54 of the 80 patients to 
reduce cortisol levels, but was not considered a curative treatment. 
For CD, TSS was performed in 36 of the 38 patients. One patient had an inoperable ACTH-
secreting pituitary adenoma and received medical therapy and radiotherapy. One patient with 
CD died before the first attempted curative treatment and was excluded from further 
calculations. The time from diagnosis of CD (N=37) to first attempted curative treatment was 
118 days (range 1-359, interquartile range 81-212). 
For unilateral cortisol producing adrenal adenoma, unilateral adrenalectomy was performed in 
all 14 patients. Both patients with PPNAD and the patient with macronodular hyperplasia had 
bilateral adrenalectomy. For the 17 patients with benign adrenal CS, the time from diagnosis to 
first treatment was 83 days (range 19-576, interquartile range 58-116). The time from diagnosis 
to first treatment did not differ significantly between CD and benign adrenal CS (P=0.090).  
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The time from diagnosis to first attempted curative treatment for CD and benign adrenal CS 
was 106 days for women (range 1-359, interquartile range 58-184) and 118 days for men (range 
1-576, interquartile range 101-183; P=0.283). 
In the 21 patients with ectopic CS, various treatments were given. Eleven patients had medical 
therapy as the sole treatment, three patients had medical therapy and oncological treatment 
(including tumor specific surgery, chemotherapy and/or radiotherapy), four patients had 
medical therapy, oncological treatment and bilateral adrenalectomy and two patients had 
medical therapy and bilateral adrenalectomy. Pulmonary lobectomy was performed in one 
patient with ACTH-positive neuroendocrine lung tumor. For ectopic CS, the median time from 
diagnosis to first attempted curative treatment was not calculated because most patients had 
received various medical and/or oncological treatments before diagnosis CS, and the treatments 
were rarely curative. 
All three patients with adrenal carcinoma received unilateral adrenalectomy, tumor specific 
therapy for metastases, various medical therapies and oncological treatments. For adrenal 
carcinoma, the time from diagnosis to first treatment was 0, 10 and 12 days. However, similar 
to ectopic CS, the given treatments for patients with adrenal carcinoma were rarely curative. 
5.4.4 Time from first treatment to remission 
In the 38 patients with CD, 35 patients (92%) were in remission at last visit. For one patient, 
remission status was uncertain and two patients with CD had died before achieving remission.  
Of the 35 patients with CD who were in remission at the last clinical visit, 24 (69%) had 
achieved remission after the first TSS and one after pituitary radiotherapy and medical 
therapy (Figure 6). Ten (29%) of the patients required additional treatments in various 
combinations. Four patients had a second TSS and one patient had a second TSS and pituitary 
radiotherapy. Two patients required pituitary radiotherapy after the first TSS and one patient 
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had bilateral adrenalectomy after the first TSS. Finally, one patient required three TSS, 
pituitary radiotherapy and bilateral adrenalectomy to achieve remission. The patient with 
aggressive ACTH-secreting pituitary tumor achieved remission 9 months following diagnosis, 
after receiving medical therapy, TSS, pituitary radiotherapy and chemotherapy.  
 
Figure	6. Treatments	and	remission	status	in	patients	with	Cushing’s	disease	(CD).	TSS	=	Trans	sphenoidal	surgery. 
 
The time from first treatment to remission in CD patients who were not in remission after the 
first attempted curative treatment and did not have recurrent disease (N=5) was 464 days 
(range 236-2055, interquartile range 248-1585).  
All 14 patients with cortisol producing adrenal adenoma achieved remission after unilateral 
adrenalectomy. Both patients with PPNAD and the patient with macronodular hyperplasia 
achieved remission after bilateral adrenalectomy. None of the three patients with cortisol 
producing adrenal carcionoma were in remission post-operatively or at the last clinical visit. 
Only three (14%) of the 21 patients with ectopic CS achieved remission; one patient with a 
ACTH-positive neuroendocrine lung tumor who achieved remission after pulmonary 
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lobectomy and two patients with unknown primary ACTH-secreting tumor who achieved 
remission after bilateral adrenalectomy. 
5.4.5 Recurrence and death 
Five (13%) of the 38 patients with CD had a relapse after 16, 25, 28, 44 and 118 months, 
respectively, after the first attempted curative treatment. Two of the patients with CD had 
died, one before TSS was performed and one who had been in remission for 7 years. None of 
the 17 patients with benign adrenal CS had a relapse and none had died at the end of the 
study. Of 21 patients diagnosed with ectopic CS, three had a relapse 34, 41 and 90 months 
after the first attempted curative treatment and 18 patients with ectopic CS had died at the end 
of the study. One of the patients with adrenal carcinoma had a relapse after 8 months and two 
of the three patients with adrenal carcinoma had died at the end of the study.  
5.4.6 Time from debut of symptoms to remission 
For patients with CD, the time from debut of symptoms to remission was 907 days (30 
months) for patients who achieved remission after the first TSS and 1371 days (46 months) 
for patients who needed additional treatments postoperatively to achieve remission. In 
patients with benign adrenal CS, the total median time from debut of symptoms to remission 
was 723 days (24 months). The timeline is shown in Figure 7. 
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Figure	7. Time	line	for	patients	with	endogenous	Cushing’s	syndrome	(CS)	in	months 
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6. Discussion 
In this project, the epidemiology of endogenous CS in West Götaland region has been studied. 
The main findings of the study are: 1) Incidence rate of all endogenous CS is 3.1 per million 
per year and the prevalence is 57 per million. 2) Of all patients with endogenous CS, 
proportionally fewer patients have CD (49%) than previously reported, and more patients 
have benign adrenal CS (21%) and ectopic CS (26%). 3) Validation of the diagnostic codes 
for CD has a sensitivity of 100% and a specificity of 70%, and for ectopic CS a sensitivity of 
62% and a specificity of 93%. 4) New diagnostic codes for adrenal CS should be added to the 
ICD-registry. 5) The total time from debut of symptoms to remission is 30-46 months for 
patients with CD and 24 months for patients with benign adrenal CS. 6) Time with 
undiagnosed CS is the longest period of the disease in patients with endogenous CS. 
 
6.1 CS in the West Götaland region 
Of 234 identified patients, 80 patients had endogenous CS. CD was found in 39 patients, 
representing 49% of patients with endogenous CS and 65% of ACTH-dependent CS. These 
results differed from previous studies where CD was reported to account for 70% of all cases 
of CS (1) and 80% of all ACTH-dependent CS (2). Ectopic CS was found in 21 patients, 
representing 26% of patients with endogenous CS and 35% of ACTH-dependent CS. In 
previous studies, ectopic CS was reported 12% of all cases of CS (1) and 20% of ACTH-
dependent CS (2). Thus, the results of this study show a larger proportion of ectopic CS than 
previously reported. 
The differences between CD and ectopic CS in this study, compared to previous studies, can 
be explained by variations in the diagnostic process and management of patients with 
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endogenous CS. Patients with ectopic CS usually have malignant tumours, and are 
consequently managed at oncology departments. Different countries and hospitals may have 
varying routines for these patients. In patients with ectopic CS, it is likely that some patients 
were never admitted to endocrinology departments and never received a CS diagnosis, 
explaining the lower rates of ectopic CS in previous studies. Furthermore, the course of 
ectopic CS is often rapid and the disease can have mortal outcome in only weeks or months, 
increasing the difficulty of identify these patients. 
In patients with ACTH-independent CS, 17 (85%) had benign adrenal CS, thus representing 
21% of all endogenous CS. Three (15%) of the patients with ACTH-independent CS had 
adrenal carcinoma, representing 4% of all endogenous CS. These results differed from 
previous reports, where proportions for adrenal adenoma and adrenal carcinoma in ACTH-
independent CS were 60 and 40%, respectively (2). Similar to ACTH-dependent CS, the 
different rates of ACTH-independent CS can be explained by differences in the management 
of these patients between countries and hospitals. For example, it is possible that patients with 
adrenal adenoma are mainly managed in departments of surgery in some hospitals, explaining 
the lower rates of adrenal adenoma in previous studies. 
 
6.2 Validation of the CS diagnosis 
Aetiology of ACTH-secreting pituitary adenoma was proven through histopathological 
diagnosis in 77% of the patients with CD in the current study, which is in line with previously 
reported rates of 74% (4). Furthermore, the vast majority of patients with CD in this study 
who had invisible or small pituitary adenoma were investigated with sinus petrosus 
catheterization. Thirty-six (92%) of the 39 patients with CD had confirmed diagnosis with 
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histopathological examination and/or sinus petrosus catheterization. Almost all patients with 
ACTH-independent CS had confirmed aetiology through histopathological diagnosis, 16 
(94%) of 17 patients with benign adrenal CS and all three patients with adrenal carcinoma.  
All 39 patients diagnosed with CD received the right diagnostic code for pituitary dependent 
CS, E24.0. The sensitivity of the diagnostic code was 100% and the specificity 70%, 
indicating well-functioning diagnostic coding for patients with CD although the diagnostic 
code was apparently also used incorrectly for several patients who did not have CD. 
In the patients with benign adrenal CS, 47% received the diagnostic code E24.8 (Other 
specified CS) and 53% received E24.9 (Unspecified CS). The fact that there is no separate 
diagnostic code for adrenal CS explains the inconsistent coding of these patients. 
The majority (62%) of the patients with ectopic CS received the right diagnostic code (E24.3). 
The remaining patients received various diagnostic codes. The sensitivity of the diagnostic 
code was only 62%, meaning that one-third of patients with ectopic CS are not captured by a 
search for this specific diagnostic code. Patients with ectopic CS are often managed at 
oncology clinics, possibly explaining the lower sensitivity of this diagnostic code. 
In the patients with adrenal carcinoma, one received E24.8 (Other specified CS) and one 
received E24.9 (Unspecified CS). The third patient with adrenal carcinoma had not received 
any diagnostic code for CS. All three patients with adrenal carcinoma received, however, the 
diagnostic code for adrenocortical cancer, C74.0. Again, since there is no separate diagnostic 
code for adrenal CS, the diagnostic coding of these patients is inconsistent. In future studies, 
the diagnostic code for adrenocortical cancer should be included in the search criteria.  
In summary, the results from the validation of the diagnostic codes for CS demonstrates that 
separate diagnostic codes for benign adrenal CS and adrenal carcinoma are needed. In fact, it 
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is odd that rarer subgroups of CS such as Nelson’s syndrome and alcohol induced CS have 
separate diagnostic codes in the current ICD-registry. Concerning alcohol induced CS, we 
suggest that this code (E24.4) should be replaced by a code for pseudo CS, since alcohol 
induced CS is included in pseudo CS. 
 
6.3 Incidence and prevalence 
Previous epidemiological studies on CS are often limited to CD (Table 4) and prevalence 
rates has, to our knowledge, only been reported in one previous study (10). In our study, the 
total incidence of endogenous CS was 3.1 per million per year. For CD, the incidence was 1.5 
per million per year, for benign adrenal CS 0.7, adrenal carcinoma 0.1 and ectopic CS 0.8. 
These incidence rates are in line with previous findings. Lindholm et al. (4) found an 
incidence of 1.2-1.7 per million per year for CD, for adrenal adenoma 0.6 and for adrenal 
carcinoma 0.2. Arnardóttir et al. (13) and Clayton et al. (14) both found an incidence of 1.5 
per million per year for CD and Bolland et al. (10) found an incidence of 1.8 per million per 
year for endogenous CS, excluding malignant ectopic CS and adrenal carcinoma. 
Furthermore, in a study on the incidence of pituitary adenomas in West Götaland region, 
Sweden (15) the total incidence of ACTH-secreting pituitary adenomas, i.e. CD, was 1.8 per 
million per year. Higher incidence rates, 2.4 per million per year for CD, were found by 
Etxabe et al. (16). Broder et al. (11) reported an exceptionally high annual incidence rate for 
all endogenous CS, 49 cases per million, and 8 cases per million for CD. Interestingly, that 
study was based on data from a large insurance database, probably greatly overestimating the 
incidence of CS. 
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Table	4.	Incidence	rates	of	endogenous	CS	in	epidemiological	studies	
 
Data	are	incidence	rates	per	million	per	year	
*Excluding	adrenal	carcinoma	and	malignant	ectopic	CS	
	
The annual incidence of endogenous CS in West Götaland Region varied, in 2003 only one 
patient was diagnosed with benign adrenal CS compared to in 2013 when 11 new cases of 
endogenous CS were reported (Figure 5). Although we cannot exclude that some patients with 
true CS may have been missed, this is probably a finding by chance. 
The prevalence rate of endogenous CS in this study was lower, 57 cases per million, than 
previously reported 79 cases per million (10). It is possible that some patients who were 
treated before 2002, who are considered cured and therefore no longer are followed at the 
endocrinology department at the Sahlgrenska University Hospital, may have been missed. 
Hence, the true prevalence rate of endogenous CS in the West Götaland region may be 
somewhat higher.  
 
6.4 Demographics 
In our study, women accounted for 70% of all endogenous CS, which is in line with previous 
reports (10). The mean age at diagnosis was 50 years. In previous studies, the mean age at 
diagnosis has been reported to be 25-50 years (1) and median age at diagnosis 36-46 years 
(14). Thus, our study showed a somewhat higher mean age at diagnosis than previously 
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reported, possibly explained by the higher proportion of patients with ectopic CS in our study. 
In fact, patients with ectopic CS (mean age 59 years) were significantly older at diagnosis 
compared to patients with CD (mean age 48 years) and benign adrenal CS (mean age 44 
years). 
At the time of diagnosis, 74% of the patients had hypertension and 33% had diabetes. In a 
previous study, the prevalence of hypertension was reported 68% and diabetes or glucose 
intolerance 80% (1). Our study found a somewhat higher prevalence of hypertension and for 
diabetes, a considerably lower prevalence than previously reported. The differences can be 
explained by variations in diagnostic criteria for hypertension, and the much higher 
prevalence of diabetes in the previous study by the fact that patients with glucose intolerance 
were also included. 
 
6.5 Timeline 
To our knowledge, a timeline from debut of symptoms to recognition, diagnosis, treatments 
and remission for patients with endogenous CS has not previously been created.  
Bolland et al. (10) reported a duration of symptoms of 2 years for CS (excluding adrenal 
carcinoma and malignant ectopic CS) which is in line with our results with duration of 
symptoms of 24 months for CD and 18 months for benign adrenal CS. Differences in time 
from first visit to the first attempted curative treatment in patients with CD compared to 
benign adrenal CS did not differ significantly. This may be a surprising finding since the 
biochemical testing for CD is often more time consuming compared to benign adrenal CS. In 
patients with adrenal adenoma, low ACTH and CT adrenal are most often sufficient to 
confirm the diagnosis and refer the patient for adrenalectomy. For patients with CD, sinus 
  41 
petrosus catheterization is frequently needed, making the diagnostic process longer. When 
comparing the time from debut of symptoms to first treatment between women and men with 
CD and benign adrenal CS, the time did not differ significantly. However, patients with 
ectopic CS had significantly shorter duration of symptoms and time from first visit to 
diagnosis than both CD and benign adrenal CS.  
Of 38 patients with CD, 35 (92%) were in remission at last visit. Of these 35 patients, 25 
(69%) achieved remission after the first TSS, one (2%) after pituitary radiotherapy and 10 
(29%) required additional treatments to achieve remission. Previous studies have reported 82-
86% remission rates after the first TSS (17) (18) and long-term remission rates of 56% (19). 
Thus, the remission rates of CD in our study, especially remission at last visit, are satisfying. 
In patients with benign adrenal CS, all 17 patients were in remission at last visit and achieved 
remission shortly after unilateral or bilateral adrenalectomy. Only three (14%) of the patients 
with ectopic CS achieved remission and none of the patients with adrenal carcinoma achieved 
remission.  
Five patients with CD (13%) had a relapse and two patients (5%) had died. The relapse rate is 
in line with previous studies where 9% of the patients with CD had recurrent disease (18). 
None of the patients with benign adrenal CS had a relapse or had died. In contrast, 18 patients 
with ectopic CS and two of the three patients with adrenal carcinoma had died at the end of 
the study. These results confirm the much poorer prognosis of ectopic CS compared to CD 
and cortisol producing adrenal adenoma (10). 
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6.6 Strengths and weaknesses 
Our search for patients was facilitated through the DRG-registry and the collected data was 
reviewed by an endocrinologist at the Sahlgrenska University Hospital who had personally 
been involved in the diagnostic work-up and treatment decisions in most of the patients 
included in the study. Also, since all patients with endogenous CS in the West Götaland 
region should be referred to the endocrinology department of the Sahlgrenska University 
Hospital, we feel confident that all patients diagnosed with CS from 2002 to 2017 in the West 
Götaland region were included in the study after searching the DRG-registry. 
However, we cannot completely rule out that some patients with endogenous CS in the West 
Götaland region who have not received any diagnostic code for CS at the Sahlgrenska 
University Hospital may have been missed. For example, it is possible that some patients with 
ectopic CS who were diagnosed and treated in local hospitals in the region and were never 
admitted to the Sahlgrenska University Hospital were missed. Thus, it is likely that the true 
incidence and prevalence rates for endogenous CS, especially for ectopic CS, are somewhat 
higher. In future studies, the DRG-registry should be searched in all local hospitals in the 
West Götaland region for the diagnostic codes of CS, and also include the diagnostic codes 
for adrenal cancer (C24.0), benign pituitary tumour (D35.2) and malign pituitary tumour 
(C75.1), to make sure that all patients with endogenous CS are identified. 
A strength of this study is the analysis of the incidence and prevalence in all subgroups of 
endogenous CS, which has not previously been done. The methods used for calculation of 
incidence and prevalence rates are generally accepted and the West Götaland region has a 
large and well-defined population. Since the calculations are based on reliable data, the 
incidence and prevalence rates should be considered accurate. However, calculations were 
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made on a relatively small study population (N=80), and subgroups of CD, benign adrenal 
CS, ectopic CS and adrenal carcinoma are even smaller, decreasing the power of the study. 
Validation of the ICD-10 codes for CS has not been reported previously. Weaknesses of the 
current ICD-registry were identified, especially the lack of diagnostic codes for adrenal CS. 
Calculations of sensitivity and specificity for the diagnostic codes E24.0 (Pituitary-dependent 
CS), E24.2 (Iatrogenic CS) and E24.3 (Ectopic CS) gives an approximate estimate of the 
reliability of the diagnostic coding for these diagnoses. However, since the sensitivity and 
specificity for benign adrenal CS and adrenal carcinoma were not estimated due to 
inconsistent coding, it is not possible to draw conclusions on the reliability of the diagnostic 
coding for all endogenous CS.  
The novel timeline analysis illustrates the time lapse from debut of symptoms through 
recognition, diagnosis and treatment to remission, and can be used to evaluate and improve 
the patient care in patients with endogenous CS. However, the timeline has several 
limitations. The dates of all patient visits were not always accessible and in some cases dates 
were roughly estimated. Thus, time differences may not be entirely accurate and would 
probably differ if they were re-calculated. Duration of symptoms was usually based on the 
patients’ own description on debut of characteristic symptoms of CS. Duration of symptoms 
is a highly subjective estimate that depends not only on the patient’s own experience of the 
symptoms but also on the treating physician’s assessment and the person that reviews the 
data. Furthermore, remission status and relapse were difficult to determine in some patients 
and estimates may not be entirely correct.  
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7. Conclusions and implications 
This study provides reliable incidence and prevalence rates for endogenous CS, with an 
overall incidence rate of 3.1 per million per year and a prevalence of 57 per million. CD was 
less common than previously reported (2), representing 49% of all patients with endogenous 
CS, while benign adrenal CS counted for 21% and ectopic CS for 26% of the patients, which 
are considerably higher numbers than previously reported (2). Although incidence and 
prevalence rates in our study were generally in line with previous reports, the study 
population and the subgroups are small. Further research, preferably on larger populations in 
different geographical areas, is necessary to establish the true incidence and prevalence rates 
of CS.  
Validation of the diagnostic codes used for CS was performed and suggestions on how to 
improve the diagnostic coding of CS are presented. Most importantly, new diagnostic codes 
for benign adrenal CS and adrenal carcinoma should be added to the ICD-registry. Our 
validation of the diagnostic codes for CS open up to further evaluation of the diagnostic 
coding not only for CS but for other diseases as well. Validation of the diagnosis is of 
paramount importance in epidemiological research of rare diseases for identification of 
patients. Additionally, adequate follow-up of these patients is facilitated through accurate 
diagnostic coding. Hence, diagnostic coding should also be considered an important matter in 
patient care.  
A timeline demonstrates the time span from debut of symptoms to remission. For patients 
with CD, the total time from debut of symptoms to remission is 30-46 months and in patients 
with benign adrenal CS 24 months. The timeline can preferably be further developed in future 
studies and should also be investigated in other hospitals for comparison. Our findings show 
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that time with undiagnosed CS prior to referral to an endocrinologist is the longest period of 
the disease. Because duration of hypercortisolism before CS diagnosis may predict increased 
mortality (9) and most patients with endogenous CS actually achieve remission with adequate 
treatment, physicians need to have CS in mind and not miss these rare patients that easily can 
be overlooked among the big group of patients with the metabolic syndrome. Since diabetes 
and in particular hypertension is frequent in patients with active CS, it is possible that 
screening for CS in these patient groups should be done more often. 
CS is associated with increased morbidity and mortality (10) and patients in long-term 
remission maintain a high cardiovascular risk (7), suggesting the importance of early 
recognition and adequate management of these patients. Our timeline can be used to further 
evaluate and improve the time lapse of the patient care in patients with endogenous CS at the 
Sahlgrenska University Hospital. Endocrinologists at the Sahlgrenska University hospital 
have established a structured short- and longterm management plan for CS patients in 
remission (20) where evaluation of cardiovascular risk, pituitary function as well as 
psychiatric symptoms are emphasized. The aspect of psychiatric dysfunction in patients with 
CS in remission is not yet fully understood and is subject for future research. 
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Populärvetenskaplig sammanfattning 
Cushing’s syndrom i västra Sverige 
Examensarbete, Läkarprogrammet 
Sofie Wengander 
Handledare: Oskar Ragnarsson, Överläkare, Docent 
2018, Avdelningen för Endokrinologi, Sahlgrenska Universitetssjukhuset, Göteborg  
Cushing’s syndrom (CS) är en ovanlig hormonsjukdom som beror på för höga nivåer av 
stresshormonet kortisol i kroppen. Kortisol är ett livsnödvändigt hormon som påverkar många 
av kroppens funktioner, bland annat sömnen, ämnesomsättningen och hjärnan. Kortisol 
tillverkas normalt av binjurarna, vars produktion i sin tur styrs från en liten körtel i hjärnan, 
hypofysen. Hypofysen tillverkar adrenokortikotropt hormon (ACTH), vilket stimulerar 
binjurarna att tillverka kortison. Hos en frisk människa reglerar kroppen själv så att nivåerna 
av kortisol i kroppen är lagom höga.  
Hos personer med CS är nivåerna av kortisol mycket höga, vilket är skadligt för kroppen. 
Personer med CS går upp i vikt, får högt blodtryck och upplever psykiska besvär. Orsaken till 
sjukdomen är oftast en tumör som tillverkar hormon. Antingen tillverkar tumören kortisol 
(binjuretumörer) eller ACTH (hypofystumörer), vilket gör att nivåerna av kortisol i kroppen 
höjs. Tumörerna är oftast godartade, även om CS i ovanligare fall kan orsakas av 
cancertumörer.  
Den vanligaste behandlingen för CS är att man opererar bort den hormontillverkande 
tumören. Oftast blir personen då botad. Forskning har dock visat att hjärt-kärlsjukdom är 
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vanligare hos personer med CS, även efter att de har blivit botade. Eftersom CS är en ovanlig 
sjukdom, finns inte mycket forskning inom området. 
I denna studie har incidens (hur många personer som insjuknar i sjukdomen per år per miljon 
invånare) beräknats för CS i Västra Götaland. Man har också undersökt hur välfungerande de 
olika diagnoskoderna för CS är, vilka används för att registrera sjukdomen i journalen. 
Dessutom har en tidslinje gjorts från att personerna med CS började känna sig sjuka tills 
första läkarbesöket, behandling och bot. 80 personer med CS som fått diagnosen i Västra 
Götaland mellan åren 2002-2017 ingår i studien. 
I studien kom man fram till att incidensen av alla typer av CS är 3 per miljon per år i Västra 
Götaland. Av personerna med CS hade 49% godartad hypofystumör, 21% godartad 
binjuretumör, 4% binjurecancer och 26% hormonproducerande cancertumör i någon annan 
del av kroppen. För personer med godartad hypofystumör tog det 30–46 månader från de 
började få symtom från sjukdomen tills de ansågs botade. För personer med godartad 
binjuretumör tog det 24 månader. Endast 14% av personerna med hormonproducerande 
cancertumörer och inga av personerna med binjurecancer botades. 
Denna studie visar nya siffror på incidens av CS som bekräftar hur ovanlig sjukdomen är. 
Andelen personer med hormonproducerande cancertumörer var större i denna studien jämfört 
med tidigare studier och mer forskning behövs för att säkerställa om detta stämmer. 
Diagnoskoderna som användes för CS visade sig vara i behov av uppdatering med nya 
diagnoskoder för binjuretumörer eftersom inga separata diagnoskoder fanns för det. 
Tidslinjen som gjordes kan användas som ett verktyg för att förbättra vården av personer med 
CS, så att sjukdomen upptäcks tidigt, rätt behandling ges och de blir botade snabbare. 
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